Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
JAMA Oncol. 2019 May 1;5(5):703-709. doi: 10.1001/jamaoncol.2018.7204.
Neurosurgical resection represents an important management strategy for patients with large, symptomatic brain metastases and increasingly is followed by stereotactic radiation as opposed to whole-brain radiation. Whether neurosurgical resection is associated with tumor spread beyond the resection site and adjuvant stereotactic radiation field remains unknown.
To characterize the association and incidence of pachymeningeal seeding with neurosurgical resection in patients with brain metastases treated with adjuvant stereotactic radiation.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of a consecutive sample of patients with newly diagnosed brain metastases managed with neurosurgical resection and stereotactic radiation (n = 318) vs radiation alone (n = 870) between 2001 and 2015.
Incidence of pachymeningeal seeding (dural and/or outer arachnoid) and leptomeningeal disease in patients treated with neurosurgical resection and stereotactic radiation vs radiation alone and the risk factors and outcomes associated with pachymeningeal seeding in patients treated with neurosurgical resection followed by stereotactic radiation.
In 1188 patients with newly diagnosed brain metastases, 133 men and 185 women (mean [SD] age, 58.9 [11.5] years) underwent neurosurgical resection. Resection was found to be associated with pachymeningeal seeding (36 of 318 patients vs 0 of 870 patients; P < .001) but not leptomeningeal disease (hazard ratio [HR], 1.14; 95% CI, 0.73-1.77; P = .56). In total, 36 (8.4%) of 428 operations were complicated by pachymeningeal seeding, with a higher incidence noted with resection of previously irradiated vs unirradiated metastases (HR, 2.39; 95% CI, 1.25-4.57; P = .008). Patients with pachymeningeal seeding had relatively low rates of subsequent development of new brain metastases and leptomeningeal disease (8 [16%] of 51 and 6 [13%] of 48, respectively). Among patients with pachymeningeal seeding, neurologic death primarily owing to progressive pachymeningeal disease accounted for 26 (72%) of 36 deaths, but when treated with salvage radiation, 49.1% of patients survived 1 year or longer.
In the era of omission of adjuvant whole-brain radiation after neurosurgical resection, pachymeningeal seeding beyond the stereotactic radiation field represents a notable oncologic event that often proves difficult to salvage. However, in some patients, disease control can be achieved with radiotherapeutic approaches.
对于患有大的、有症状的脑转移瘤的患者,神经外科切除术是一种重要的治疗策略,而且越来越多地采用立体定向放疗来代替全脑放疗。神经外科切除术后是否与肿瘤扩散到切除部位之外以及辅助立体定向放疗野有关仍不清楚。
描述在接受辅助立体定向放疗的脑转移瘤患者中,神经外科切除术后与脑膜播散相关的特征和发生率。
设计、地点和参与者:这是一项回顾性队列研究,对 2001 年至 2015 年间接受神经外科切除术和立体定向放疗(n=318)与单纯放疗(n=870)治疗的新诊断脑转移瘤患者的连续样本进行了研究。
接受神经外科切除术和立体定向放疗的患者中脑膜种植(硬脑膜和/或外蛛网膜)和软脑膜疾病的发生率,以及接受神经外科切除术和立体定向放疗的患者中与脑膜种植相关的风险因素和结局。
在 1188 例新诊断的脑转移瘤患者中,有 133 名男性和 185 名女性(平均[SD]年龄,58.9[11.5]岁)接受了神经外科切除术。研究发现,切除术与脑膜种植(36 例患者中有 318 例 vs 870 例患者中有 0 例;P<.001)有关,但与软脑膜疾病无关(风险比[HR],1.14;95%CI,0.73-1.77;P=0.56)。总共 428 例手术中有 36 例(8.4%)并发脑膜种植,与之前接受放疗的转移瘤相比,未接受放疗的转移瘤的脑膜种植发生率更高(HR,2.39;95%CI,1.25-4.57;P=0.008)。脑膜种植的患者随后发生新发脑转移瘤和软脑膜疾病的比率相对较低(51 例中有 8 例[16%],48 例中有 6 例[13%])。在脑膜种植的患者中,主要由于进展性脑膜疾病导致的神经死亡占 36 例死亡患者中的 26 例(72%),但如果接受挽救性放疗,49.1%的患者可以存活 1 年或更长时间。
在神经外科切除术后放弃辅助全脑放疗的时代,立体定向放疗野之外的脑膜种植代表了一个显著的肿瘤事件,通常难以挽救。然而,在某些患者中,放射治疗方法可以控制疾病。